When PNB MetLife India Insurance Company Limited published its audited financial results for the year ended March 31, 2026 — approved at a Board meeting on May 14, 2026 — the numbers told a story of growth under pressure. Premium income expanded, the balance sheet swelled by over ₹6,400 crore in total assets, and the audit by joint statutory auditors K.S. Aiyar & Co. and CNK & Associates LLP returned an unmodified opinion. Not a headline-grabbing blockbuster, but the kind of disciplined execution that long-term investors quietly applaud.
What follows is a deep, multi-layered look at every significant dimension of those results — from the quarterly pulse to the annual sweep, from top-line momentum to the nuances of the combined ratio, and from the renewed board to the implications of a completed rights issue.
The Premium Engine Fires Up
The most straightforward measure of an insurer's commercial vitality is how fast it is writing new business. By this yardstick, FY26 was a solid year for PNB MetLife. Gross Written Premium (GWP) grew from ₹11,746 Cr in FY25 to ₹13,047 Cr in FY26 — a rise of roughly ₹1,301 Cr (+11.1%). Net Earned Premium (NEP) tracked closely behind, rising from ₹11,321 Cr to ₹12,587 Cr.
The Q4FY26 quarter alone was remarkable: GWP hit ₹4,431 Cr, compared to ₹3,831 Cr in Q4FY25 — a quarterly leap of +15.7%. This acceleration suggests either a strong March push, seasonal tail winds, or both, and reflects well on the company's distribution muscle — particularly given PNB's vast branch network that underpins the bancassurance channel.
The P&L on Sale of Investments came in at ₹3,074 Cr in FY26 versus ₹3,324 Cr in FY25 — a ₹250 Cr moderation. This softer investment income partially explains why total revenue growth (+7%) lagged behind the stellar premium growth (+11%), a factor worth watching if equity market conditions remain choppy in FY27.
Profitability: The Tightrope Walk
The bottom line tells a nuanced tale. At the full-year level, PAT held essentially flat at ₹320 Cr versus ₹325 Cr — a barely perceptible ₹5 Cr dip (-1.5%). For an insurer growing its premium book at double-digit rates, near-flat profits reveal deliberate investment in growth infrastructure — higher distribution costs, expanded headcount, or increased actuarial provisioning.
| Particulars | FY26 | FY25 | Change |
|---|---|---|---|
| Gross Written Premium | 13,047 | 11,746 | +11.1% |
| Net Earned Premium | 12,587 | 11,321 | +11.2% |
| Total Revenue | 15,990 | 14,946 | +7.0% |
| Claims Incurred | 6,517 | 5,670 | +14.9% |
| Commission | 794 | 764 | +3.9% |
| Operating Expenses | 1,756 | 1,489 | +17.9% |
| Operating Profit | 434 | 480 | −9.6% |
| PBT | 320 | 325 | −1.5% |
| PAT | 320 | 325 | −1.5% |
The quarterly picture is, frankly, more sobering. Q4FY26 operating profit slipped to ₹155 Cr from ₹237 Cr in Q4FY25 — a −34.6% decline. And PBT in Q4FY26 came in at ₹74 Cr, down from ₹113 Cr. The primary culprit is visible in the cost lines: operating expenses in Q4FY26 jumped to ₹555 Cr against ₹427 Cr a year prior, a +30% quarterly surge. This likely reflects year-end provisioning, salary revisions, and technology investments.
Growing your premium book at 11% while holding PAT near-flat is not failure — it is a conscious choice to invest today in the distribution, technology and talent that will compound tomorrow.
— Analysis, UnlistedZone ResearchThe Ratio Story: Efficiency in Focus
Insurance efficiency ratios are the vital signs of the underwriting body. Three ratios dominate the conversation for PNB MetLife.
The Combined Ratio nudged up to 72.03% from 69.98%. While still a very healthy reading (anything below 100% means the company is profitable on its underwriting book), the 205-basis-point uptick confirms cost pressures are real.
The Claim Ratio moved from 50.08% to 51.78% — climbing claims incurred (₹6,517 Cr vs ₹5,670 Cr, a +14.9% jump) outpaced premium growth. One bright spot: the Commission Ratio actually improved — falling to 6.09% from 6.50%.
A Balance Sheet Built for Scale
The balance sheet grew by over ₹6,400 crore in a single year. Shareholders' funds leapt from ₹4,520 Cr to ₹5,766 Cr — a 27.6% expansion — partly fuelled by a rights issue in which 3,65,85,363 equity shares were allotted at ₹82 per share, raising ₹300 Cr.
The solvency ratio stood at a comfortable 197% as of Q4FY26 — well above the IRDAI's 150% regulatory threshold. The debt-equity ratio improved to 0.15x from 0.19x, and the asset cover for NCDs stands at an impressive 770%.
Segment by Segment: Where the Growth Lives
Non-Participating Life (Segment E) emerged as the dominant profit centre with a surplus of ₹32,153 lakh, followed closely by Non-Participating Annuity and Pension (Segment F) at ₹30,642 lakh.
Persistency
| Cohort | Q4 FY26 | YTD FY26 | FY25 |
|---|---|---|---|
| 13th Month | 69.82% | 64.11% | 82.51% |
| 25th Month | 65.94% | 62.10% | 62.09% |
| 37th Month | 57.46% | 59.63% | 59.56% |
| 49th Month | 50.19% | 55.11% | 55.01% |
| 61st Month | 49.95% | 50.55% | 49.54% |
The 13th month persistency YTD FY26 figure of 64.11% is softer than the FY25 comparison of 82.51%. The Q4FY26 standalone reading of 69.82% suggests some recovery. Longer-duration persistency (49th and 61st months) has held steady around 50–55% — broadly consistent with industry norms.
Every policy that lapses at the 13th month means a customer who bought insurance and then walked away. Improving first-year persistency is one of the highest-return levers available to any life insurer's management team.
Four New Faces at the Boardroom Table
The inclusion of Genghui Wu and Marc Parich signals MetLife Inc.'s continued strategic engagement with the Indian franchise. The refreshed board could accelerate decisions around product innovation, digital transformation, and potentially a future IPO.
The Rights Issue: A Vote of Confidence
During FY2025-26, PNB MetLife executed a rights issue — a clean signal that existing shareholders believe in the growth story. A total of 3,65,85,363 fully paid equity shares were allotted at ₹82 per share (face value ₹10 + premium ₹72). The paid-up equity capital now stands at ₹2,04,947 lakhs.
The Road to FY27: Headwinds, Tailwinds, and Wild Cards
| Theme | Current Status | Direction |
|---|---|---|
| Premium Growth Momentum | 11.1% GWP growth | Accelerate |
| Claims Management | Claim ratio at 51.78% | Watch Closely |
| Operating Cost Discipline | OpEx up 17.9% YoY | Needs Containment |
| 13th Month Persistency | 64.11% YTD | Improvement Needed |
| Capital Adequacy (Solvency) | 197% — 2× regulatory minimum | Comfortable |
| Commission Efficiency | Ratio fell to 6.09% | Positive Trend |
| AUM Growth | Total assets ₹61,467 Cr | Strong Trajectory |
| Board Renewal & Governance | 4 new directors added | Strengthening |
| Non-Par / Annuity Segment | Dominant profit contributor | Growing |
The central thesis: PNB MetLife enters FY27 as a financially sound, growing insurer with a robust solvency cushion and expanding AUM — but one that must tackle a creeping claims ratio, sluggish first-year persistency, and operational costs rising faster than revenues.
The balance sheet says: we are secure. The P&L says: we are growing. The persistency numbers say: we still have work to do on keeping customers for life, not just for a year.
— Summary Assessment, UnlistedZone FY26 ReviewWhat Is PNB MetLife Worth?
With 2,04,94,69,646 shares outstanding and the most recent rights issue priced at ₹82 per share, a back-of-the-envelope market capitalisation for PNB MetLife comes to approximately ₹16,806 crore — making it a mid-cap insurer by listed market standards, but one that punches significantly above its weight on operational metrics.
÷ ₹13,047 Cr GWP (FY26)
÷ ₹320 Cr PAT (FY26)
÷ ₹61,467 Cr Total Assets
÷ ₹5,766 Cr Shareholders Fund
| Company | GWP (FY26) | MCap / Valuation | MCap / GWP | 13M Persistency | PAT |
|---|---|---|---|---|---|
| SBI Life | ₹1,00,286 Cr | ₹1,86,000 Cr | 1.85× | 87.94% ✓ | ₹2,470 Cr |
| HDFC Life | ₹1,01,290 Cr | ₹1,30,000 Cr | 1.28× | 84.9% ✓ | ₹1,912 Cr |
| ICICI Prudential | ₹53,124 Cr | ₹74,000 Cr | 1.39× | 84.5% ✓ | ~₹2,050 Cr |
| Bharti Life (deal) | ₹3,256 Cr | ₹4,667 Cr | 1.43× | 64.5% | Loss (₹74 Cr) |
| PNB MetLife (rights price) | ₹13,047 Cr | ₹16,806 Cr | 1.29× | 64.11% | ₹320 Cr ✓ |
The peer table puts PNB MetLife's 1.29× MCap/GWP in sharp relief. It sits below the Bharti Life deal multiple of 1.43× — notable because Bharti Life is loss-making with comparable persistency challenges, yet transacted at a higher revenue multiple. PNB MetLife, by contrast, is profitable (PAT ₹320 Cr), solvent at 197%, and growing at 11% — which makes the rights-issue-implied valuation look conservative relative to where deal markets are clearing. The gap to SBI Life (1.85×) is explained by scale, brand, and listed-market liquidity premium — but the gap to Bharti Life is the more interesting conversation.
The Verdict
PNB MetLife's FY26 annual results are the financial equivalent of a marathon runner at the 30-kilometre mark — strong fundamentals, disciplined form, but entering the phase where mental fortitude and strategic focus matter as much as raw capability.
The company has done what matters most: grown its premium franchise meaningfully, kept its balance sheet fortress-like, maintained solvency well above regulatory minimums, and refreshed its governance architecture. The concerns — rising claims, higher operating costs, below-par early persistency — are real, but they are the concerns of a growing business, not a distressed one.
Watch FY27. The pieces are on the board. The game is getting interesting.